PCSK9 and type 2 diabetes mellitus: A recent comprehensive meta-analysis encompassing multiple randomized controlled trials demonstrated that the use of PCSK9 inhibitors in patients with T2DM resulted in a significant reduction in MACE without causing any detrimental effects on glycemic indices or increasing the incidence of new-onset diabetes [11].